Fixed-Dose Parkinson's Combination Therapy Merging Agonist and MAO Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as those involving levodopa and dopamine agonists, face efficacy decline due to ongoing neurodegeneration, and existing combination therapies do not fully address the progressive nature of the disease.
Innovation Solution
A fixed dose combination of two active agents, including a dopamine receptor agonist and a MAO inhibitor, or other neuroprotective/symptomatic compounds, formulated in specific molar ratios to enhance pharmacokinetic properties and synergistic therapeutic effects, offering improved absorption, half-life, and distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa and dopamine agonists are administered alone, then symptomatic relief is achieved, but efficacy decreases over time due to continuing neurodegeneration
Solution Approach 1:
The patent combines multiple Parkinson's disease medications (dopamine agonist, MAO inhibitor, and amantadine) into a single fixed-dose combination tablet. This merging of therapies addresses the limitation of single-agent treatments by providing synergistic effects that maintain therapeutic efficacy over time despite progressive neurodegeneration, directly resolving the contradiction between sustained reliability and duration of action.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing three distinct active ingredients with different mechanisms of action. This composite approach allows the medication to address multiple aspects of Parkinson's pathology simultaneously, thereby maintaining reliable symptom control and neuroprotection over the long term, overcoming the efficacy decline seen with monotherapies.
2Reliability
If multiple Parkinson's medications are combined, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent merges three separate medications into one unified fixed-dose combination tablet, maintaining the therapeutic benefits of polypharmacy while eliminating the complexity of managing multiple separate prescriptions. Patients take a single tablet instead of multiple medications, directly resolving the contradiction between improved efficacy and reduced treatment complexity.
Solution Approach 2:
The combination tablet serves multiple therapeutic functions simultaneously: it provides dopaminergic stimulation, inhibits MAO-B, and offers NMDA receptor antagonism. This multi-functionality in a single formulation maintains comprehensive therapeutic efficacy while simplifying the treatment regimen, addressing both sides of the contradiction.
3Reliability
If dopamine agonist and MAO inhibitor are used in combination, then neuroprotective effects are enhanced, but pharmacokinetic optimization is required
Solution Approach 1:
The patent optimizes the pharmacokinetic parameters of the combination formulation by carefully selecting the dosages and ratios of the dopamine agonist and MAO inhibitor. This parameter optimization ensures that the neuroprotective effects are enhanced while maintaining safe and effective plasma concentration levels, directly addressing the contradiction between improved neuroprotection and pharmacokinetic manageability.
Data Source
Figure 1A~1B
Figure 1C~2A
Figure 2B~2C
AI summary
Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release